83 results
424B3
NBSE
NeuBase Therapeutics Inc
10 Aug 23
Prospectus supplement
5:13pm
”) pursuant to an engagement letter in connection with the Purchase Agreements and the offerings contemplated thereunder.
We will not receive any … ”), before deducting placement agent fees and other estimated offering expenses payable by us.
Pursuant to an engagement letter, dated as of June 12
S-1
EX-5.1
6p5azvt7g
28 Jul 23
IPO registration
6:03am
S-1
tp6mkpo owy538jknbi
28 Jul 23
IPO registration
6:03am
8-K
q0ysyrzwez jgqueo
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
424B5
g5s9cwfujnecsrtv1j
30 Jun 23
Prospectus supplement for primary offering
8:42am
8-K
EX-99.1
zlkvatz ezl2w
22 May 23
Regulation FD Disclosure
7:00am
424B5
1wyolj9k0dw2ue3i41
29 Dec 22
Prospectus supplement for primary offering
5:03pm
8-K
EX-99.1
edqt030mkw4ldf syb
21 Dec 22
NeuBase Therapeutics Reports Business Update and Financial Results
8:10am
8-K
EX-99.1
l7o7rse85ph
14 Oct 22
NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing
4:20pm
8-K
EX-99.1
jpf6nw5h7sg
11 Aug 22
NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022
8:05am
8-K
EX-99.1
dez3 lw38w
29 Jun 22
NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO
8:03am